SCHEMBL25786838

SCHEMBL25786838

Cc1nn(CCN)c(C)c1-c1ccccc1Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ BCDIN3D Q7Z5W3 2/20 0.42
▸ YAP1 P46937 1/20 0.40
▸ TEAD4 Q15561 1/20 0.40
▸ TEAD2 Q15562 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.39
▸ IDH2 P48735 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21749237 0.90 ALDH1A1 (0.44) ALDH1A1GAAMAPTRAB9ASMN1; SMN2
SCHEMBL25786817 0.85 LMNA (0.47) ALDH1A1GAAMAPTRAB9ASMN1; SMN2
SCHEMBL20553004 0.84 LMNA (0.48) GAAMAPTYAP1TEAD4TEAD2
SCHEMBL20553072 0.81 LMNA (0.45) YAP1TEAD4TEAD2LMNARECQL
SCHEMBL25786834 0.80 KCNK18 (0.38) ALDH1A1GAAMAPTRAB9ASMN1; SMN2
SCHEMBL20553542 0.78 BRAF (0.41) ALDH1A1GAAMAPTRAB9ABCDIN3D
SCHEMBL25786811 0.77 KCNK18 (0.35) ALDH1A1GAAMAPTRAB9ASMN1; SMN2
SCHEMBL21749307 0.76 MAPT (0.49) ALDH1A1GAAMAPTRAB9ASMN1; SMN2
SCHEMBL25786802 0.74 HTT (0.41) MAPTSMN1; SMN2YAP1TEAD4TEAD2
SCHEMBL20552230 0.73 ALDH1A1 (0.45) ALDH1A1GAAMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 ALDH1A1 3323/4885GAA 3205/4885MAPT 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback